Physician profile
Libby Thomas
NPI 1033933999
$2,480.39
in general payments reported to CMS, 2019-2025
24 companies · $2,215 in 2025
The $2,215 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $265 · 2025: $2,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,480.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $404.37 | 2024-2025 | Mavenclad |
| Ucb, INC. | $356.05 | 2024-2025 | Nayzilam, Briviact, Rystiggo |
| Lundbeck LLC | $207.79 | 2024-2025 | Vyepti, Rexulti |
| Abbvie INC. | $198.62 | 2024-2025 | |
| Neurelis, INC. | $140.97 | 2024-2025 | Valtoco |
| Biogen, INC. | $135.88 | 2025 | Leqembi |
| Amgen INC. | $122.08 | 2024-2025 | Uplizna |
| Argenx US, INC. | $118.39 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $104.92 | 2025 | |
| Csl Behring | $89.32 | 2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $87.23 | 2025 | Hyqvia |
| Pfizer INC. | $75.42 | 2025 | |
| Genentech USA, INC. | $69.02 | 2025 | Ocrevus Zunovo |
| Acadia Pharmaceuticals INC | $66.28 | 2024-2025 | Nuplazid |
| Sk Life Science, INC. | $65.77 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $62.05 | 2025 | Ultomiris |
| Axsome Therapeutics, INC. | $53.63 | 2025 | Symbravo, Auvelity |
| C2n Diagnostics, LLC | $22.59 | 2025 | Precivityad2 |
| Grifols USA, LLC | $21.96 | 2025 | Gamunex-C |
| Averitas Pharma INC. | $18.35 | 2025 | Qutenza |
| Lilly USA, LLC | $17.54 | 2024 | Emgality |
| Vanda Pharmaceuticals INC. | $16.58 | 2025 | Ponvory |
| Amneal Pharmaceuticals LLC | $16.15 | 2025 | Crexont |
| Aucta Pharmaceuticals, INC. | $9.43 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Libby Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.